This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Recently published research shows a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aortic valve replacement, a type of heartvalve operation.
When a patient needs a new heartvalve, the current mechanical and tissue replacements each have strengths and weaknesses. Now, a team of researchers believe they have found a way to harness the strengths of both technologies in a way that could be life-changing -- and life-saving -- for many.
Griepp , MD Professor in Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai , was named as the new President of the HeartValve Society ( HVS ) at the 2024 HVS Annual Meeting on Wednesday, February 21, in Boston.
Human skin cells have been reprogrammed into heartvalve cells and then used to successfully transplant a pig heartvalve into a rodent, led by the research of a Northeastern University professor.
The sheer scale of undiagnosed heartvalve disease in our aging population has been revealed for the first time, thanks to new research led by the University of East Anglia.
When a patient needs a new heartvalve, the current mechanical and tissue replacements each have strengths and weaknesses. Now, a team of UBC Okanagan researchers believe they have found a way to harness the strengths of both technologies in a way that could be life-changing—and life-saving—for many.
These key takeaways from the research letter on IVL-facilitated valvuloplasty for severely calcified mitral valve stenosis are published in the Journal of the American College of Cardiology (JACC) Cardiovascular Interventions. The research letter’s lead author, Gennaro Giustino, M.D.,
Findings from a published case series research letter by the Henry Ford Health Structural Heart Disease team show that severe mitral stenosis, due to a build-up of calcium deposits in the mitral valve common in elderly patients, can be safely and successfully treated using Intravascular lithotripsy (IVL)-enabled percutaneous balloon mitral valvuloplasty. (..)
Barr’s death at 39 from sudden cardiac arrest was caused by mitral valve prolapse—a heartvalve defect that can affect the heart’s ability to pump blood. This individualized approach is unique. What excites you about the future of heartvalve disease study? It can, in some cases, lead to death.
Research Highlights: An analysis of death certificate data from 1999 to 2020 showed a decline in deaths related to infective endocarditis throughout most of the United States yet found an alarming increase of 2%-5% among adults ages 25-44. There was.
Research Highlights: Edoxaban, a medication taken orally to prevent blood clots from forming, was found to be as effective and safe for stroke and blood clot prevention in patients after heartvalve replacement surgery as warfarin, the current.
Combining a biological heart and a silicone robotic pump, researchers created a biorobotic heart that beats like a real one, with a focus on a valve on the left side of the heart.
Replacement heartvalves that grow inside the body are a step closer to reality following studies led by researchers at Imperial. The results are published in Communications Biology.
Getty Images milla1cf Fri, 06/07/2024 - 15:10 June 7, 2024 — Calcific aortic valve disease (CAVD) is the major heartvalve disease that afflicts nearly 10 million patients globally with an annual mortality exceeding 100,000, and the numbers continue to rise.
This qualitative study explores the perceived benefits and intervention-specific needs of patients who received expectation-focused intervention in the context of heartvalve surgery. In addition, it explores potential barriers and adverse effects.
(MedPage Today) -- Undiagnosed heartvalve disease was highly prevalent in a large community study of otherwise healthy people recruited from primary care in the U.K., researchers found. There was a 28.2% prevalence of mild, moderate, or severe.
A team of researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid has identified the molecular mechanisms that control the activity of genes involved in both the correct formation of the heartvalves and the prevention of their subsequent calcification.
Combining a biological heart and a silicone robotic pump, researchers created a biorobotic heart that beats like a real one, focusing on a valve on the left side of the heart.
In such scenarios, cardiologists’ primary form of treatment for children with coronary heart disease is a heartvalve implant. Unfortunately, the traditional pulmonary valves have a fixed diameter that can’t match the size of the child’s heart over time.
BACKGROUND:A main obstacle in current valvular heart disease research is the lack of high-quality homogeneous functional heartvalve cells. Human induced pluripotent stem cells (hiPSCs)-derived heartvalve cells may help with this dilemma.
Although well-known for their thromboresistance, bileaflet mechanical heartvalves (BMHV) require lifelong anti-thrombotic therapy. This must be associated with a certain level of thrombogenicity. Since both t.
within the last two decades, yet accelerated among young adults ages 25 to 44 years old, according to new research published in the Journal of the American Heart Association. Death rates related to infective endocarditis declined in most adults across the U.S.
Background Valvular heart disease is a major health concern worldwide. The effective management of patients undergoing valve replacement determines their prognosis. Bibliometric analysis of studies on managing patients with artificial heartvalves has not been previously performed.
This study aims to compare the efficacy of the Age-adjusted Charlson Comorbidity Index (ACCI) and the Elixhauser-Van Walraven Comorbidity Index (ECI-VW) in predicting mortality risk among patients undergoing h.
Ismail El-Hamamsy, MD, PhD, Named President of the HeartValve Society 2. Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure 7. Machine Learning Informs a New Tool to Guide Treatment for Acute Decompensated Heart Failure 8.
However, with the compelling evidence on the safety and efficacy of transcatheter aortic valve replacement (TAVR), it has become the gold standard treatment option for many patients with symptomatic severe AS. Transfemoral access has been the preferred method for transcatheter heartvalve delivery.
Stroke is a potentially debilitating complication of heartvalve replacement surgery, with rates ranging from 1 to 10%. Despite advancements in surgical techniques, the incidence of postoperative stroke remain.
In the heart of Adana, the Adana City Health Training and Research Center recently became the epicenter of groundbreaking advancements in medical education. Last week marked a significant milestone as the center of excellence for Transcatheter Aortic Valve Implantation (TAVI) procedures hosted a highly successful TAVI Masterclass.
Doctors at Mayo Clinic have used a new catheter-based approach to draw out resistant pockets of infection that settle in the heart, known as right-sided infective endocarditis, without surgery. Unless treated quickly, the walled-off infections can grow, severely damaging heartvalves and potentially affecting other organs as well.
The aim of this study was to identify the risk factors for postoperative delirium (POD) in elderly patients undergoing heartvalve surgery with cardiopulmonary bypass (CPB).
Research Highlights: Artificial intelligence (AI) and deep learning models may help to predict the risk of cardiovascular disease events and detect heart valvular disease, according to two preliminary research studies. One study found that artificial.
The Center will also focus on clinical trials for transcatheter edge-to-edge repair (TEER) devices for tricuspid regurgitation, new devices for transcatheter mitral valve replacement, and advancing the field of robotic valve surgery. “At
Photo by Cedars-Sinai milla1cf Mon, 06/24/2024 - 20:17 June 24, 2024 — Aakriti Gupta, MD , and Michelle Kittleson, MD, PhD , cardiologists in the Smidt Heart Institute at Cedars-Sinai , have been selected to join the senior editorial team of the Journal of the American College of Cardiology (JACC), effective July 1.
The first cases were performed by Dr. Tamim Nazif , Director of Clinical Research, Dr. Susheel Kodali , Professor of Medicine and Director of the Structural Heart and Valve Center , and Dr. Isaac George , Surgical Director of the HeartValve Center.
Severe disease is managed with valve replacement procedures, which entail high health care–related costs and postprocedural morbidity and mortality. Robust ongoing research programs have elucidated many important molecular pathways contributing to primary valvular heart disease.
Image courtesy of Henry Ford Health milla1cf Wed, 02/21/2024 - 19:07 February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart disease patient—and the first ever in Michigan—to receive a new transcatheter heartvalve device for treating severe tricuspid regurgitation.
The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine. Sinai Hospital (New York, NY).
Cardiogenic dementia is a cognitive impairment caused by heart dysfunction and has received increasing research attention. This study describes the changes in cognitive function associated with coronary artery disease, myocardial infarction, heart failure, atrial fibrillation and heartvalve disease.
The research is funded by a four-year, $7.8 million grant awarded to Georgia Tech by the United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP) as part of the agency’s call for the development of less invasive treatment technologies for cardiovascular conditions associated with cardiomyopathy.
BackgroundEmerging evidence indicates a significant link between various immune cell types and the development of heartvalve disorders. Mitral valve prolapse (MVP) is a common condition that can lead to heart failure, arrhythmias, and even sudden death. Currently, the role of immune cells in MVP is not well understood.
Some patients who receive heartvalve implants develop dangerous blood clots, and researchers from the University of Waterloo contributed to an international collaboration that reduces the risk.
This manual presents findings from implementing the INCREASE study, a bicentric prospective randomized controlled trial focusing on ERAS in minimally invasive heartvalve surgery.MethodsUtilizing the Consolidated Framework for Implementation Research (CFIR) and the Template for Intervention Description and Replication (TIDieR), the study examined contextual (..)
Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. ESC-EORP, European Society of Cardiology-EURObservational Research Programme; TV, tricuspid valve.
Methods We included consecutive patients undergoing COMBO and M-TEER between March 2015 and April 2018 at our HeartValve Center, while excluding patients presenting a case of redo or with previous MV surgery. Aims To evaluate the procedural and clinical outcome of COMBO therapies compared with M-TEER alone.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content